GET DAILY SIGNALSUniversal Health Services (UHS) Delivers Q3 Revenue Growth of 5.3% but Margin Pressure Persists
Key Takeaways
- Net revenue increased 5.3% year over year to $4.73 billion, aligning closely with analyst expectations of roughly $4.71 billion.
- Adjusted earnings per share reached $5.22, slightly above the consensus estimate of about $5.15 yet lower than the $5.69 recorded in the prior-year quarter.
- Adjusted EBITDA totaled $624.6 million, below the anticipated $634.9 million.
- The adjusted operating margin narrowed to 10.2%, a 1.4 percentage point decline from the year-ago period, even as same-store sales rose 4.7%.
- Universal Health Services posted third-quarter net income of $308.7 million and bought back 1.35 million shares for approximately $242.1 million.
Why These Results Matter in Context
Universal Health Services operates as one of the largest providers of hospital and behavioral health services in the country. Its quarterly performance offers useful signals on labor expenses, patient volumes, and reimbursement dynamics affecting the broader sector. This third-quarter report followed a difficult second quarter marked by revenue outperformance alongside reduced full-year EPS guidance and the loss of licenses at two behavioral health facilities. With attention centered on whether margins in the behavioral health area were beginning to stabilize, the latest numbers provided an important check on the company’s handling of higher operating costs alongside continued revenue expansion.
The Quarter’s Reported Figures
Universal Health Services posted third-quarter 2026 net revenue of $4.73 billion, representing a 5.3% increase from the same period a year earlier and essentially matching the consensus estimate near $4.71 billion. Same-store sales advanced 4.7% year over year, an improvement over the 2% growth seen in the comparable quarter. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Adjusted EPS came in at $5.22, a modest beat versus the roughly $5.15 consensus but below the $5.69 from the prior year. Net income reached $308.7 million. Adjusted EBITDA stood at $624.6 million, missing the expected $634.9 million and equating to a 13.2% margin. Profitability faced ongoing headwinds, with the adjusted operating margin falling to 10.2%—down 1.4 percentage points year over year—and the reported operating margin declining to 9.6% from 11.6%. The results incorporated a net favorable pre-tax effect of about $21 million from Medicaid supplemental payments, offset in part by a $26 million unfavorable pre-tax charge related to higher reserves for self-insured claims.
How the Market Responded
The market reaction stayed relatively subdued. Shares finished the release day near $177.32 and showed little movement in early after-hours trading, consistent with a mixed quarter where a small EPS beat was tempered by the EBITDA shortfall and continued margin compression. The stock had risen about 5% over the preceding three months but remained down roughly 19% over the trailing 12 months, highlighting ongoing investor caution around cost pressures and the pace of recovery in behavioral health.
What to Watch Going Forward
Looking ahead, several areas deserve close attention. Management had previously guided to full-year 2026 net revenue in the range of $18.417 billion to $18.789 billion, adjusted EBITDA net of noncontrolling interests between $2.641 billion and $2.789 billion, and EPS between $22.64 and $24.52. A key focus remains whether the behavioral health segment can stabilize margins after the licensing issues and ongoing litigation. Labor costs, particularly salaries, wages, and benefits, continue to represent a major variable for profitability, and any sustained reduction in staffing expenses could aid margin improvement. Changes in Medicaid reimbursement also warrant monitoring, as the company noted their potential effect on annual results. Finally, capital allocation through the share repurchase program, with roughly $735.4 million still authorized, may influence per-share outcomes in coming quarters. From what I see, tracking these elements will be essential for assessing the company’s trajectory.
Insights from AI-Assisted Research
In preparing this review, I turned to Tickeron’s AI Screener to quickly surface comparable healthcare names and evaluate how UHS stacks up on technical and fundamental metrics. The tool allowed me to filter across the sector efficiently and confirm that the margin pressures observed here appear consistent with broader industry trends right now. This approach helped refine my perspective without replacing the core fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
UHS in -1.29% downward trend, falling for three consecutive days on October 26, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where UHS declined for three days, in 186 of 283 cases, the price declined further within the following month. The odds of a continued downward trend are 66%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for UHS moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In 21 of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at 48%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
UHS broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on UHS as a result. In 69 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for UHS just turned positive on October 14, 2026. Looking at past instances where UHS's MACD turned positive, the stock continued to rise in 28 of 42 cases over the following month. The odds of a continued upward trend are 67%.
Following a +4.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where UHS advanced for three days, in 236 of 330 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
The Aroon Indicator entered an Uptrend today. In 196 of 298 cases where UHS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 66%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. UHS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 45 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.457) is normal, around the industry mean (204.173). P/E Ratio (7.497) is within average values for comparable stocks, (19.535). Projected Growth (PEG Ratio) (1.197) is also within normal values, averaging (2.498). Dividend Yield (0.004) settles around the average of (0.099) among similar stocks. P/S Ratio (0.621) is also within normal values, averaging (2.688).
The Tickeron Profit vs. Risk Rating rating for this company is 70 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UHS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a healthcare management company, which owns and operates acute care hospitals, behavioral health centers, surgical hospitals, ambulatory surgery centers and radiation oncology centers
Industry HospitalNursingManagement
Advertisement